Sight Sciences, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $77.4M | $79.9M | $81.1M | $71.3M | $49.0M |
| Cost of revenue | $10.7M | $11.6M | $11.9M | $12.4M | $8.6M |
| Gross profit | $66.7M | $68.3M | $69.2M | $59.0M | $40.3M |
| Selling, general & administrative | $89.2M | $100.8M | $108.9M | $120.1M | $76.2M |
| Research and development | $14.6M | $18.0M | $17.6M | $22.9M | $15.6M |
| Operating expenses | $103.8M | $118.8M | $126.4M | $142.9M | $91.8M |
| Operating income | -$37.1M | -$50.5M | -$57.3M | -$84.0M | -$51.5M |
| Interest expense | $5.1M | $4.7M | $5.4M | $4.5M | $4.4M |
| Pretax income | -$38.4M | -$51.3M | -$55.4M | -$86.2M | -$62.8M |
| Income tax expense | $10,000 | $236,000 | $110,000 | $47,000 | $188,000 |
| Net income | -$38.4M | -$51.5M | -$55.5M | -$86.2M | -$63.0M |
| Balance Sheet | |||||
| Cash and equivalents | $92.0M | $120.4M | $138.1M | $185.0M | $260.7M |
| Current assets | $112.7M | $139.8M | $162.9M | $209.7M | $277.0M |
| Total assets | $115.3M | $142.8M | $166.7M | $213.1M | $280.2M |
| Current liabilities | $11.0M | $15.5M | $12.3M | $17.8M | $13.5M |
| Total liabilities | $51.4M | $55.3M | $46.4M | $53.0M | $48.1M |
| Total debt | $40.3M | $39.4M | $33.9M | $33.3M | $32.7M |
| Stockholders' equity | $63.9M | $87.5M | $120.2M | $160.1M | $232.1M |
| Cash Flow Statement | |||||
| Cash from operations | -$29.7M | -$22.4M | -$47.2M | -$76.0M | -$52.5M |
| Depreciation and amortization | $487,000 | $712,000 | $614,000 | $710,000 | $632,000 |
| Stock-based compensation | $13.1M | $17.1M | $14.6M | $13.0M | $5.1M |
| Capital expenditure | $224,000 | $385,000 | $791,000 | $970,000 | $813,000 |
| Free cash flow | -$29.9M | -$22.7M | -$48.0M | -$76.9M | -$53.4M |
| Dividends paid | $0 | $0 | $0 | — | $0 |
| Impairments | $0 | $0 | $0 | $0 | $0 |
Shares outstanding 54.4M · Free float 43.2%
Annual filing data through FY ended December 31, 2025; float as of July 14, 2026.